Edouard Nice简历_Monash University, AustraliaProfessorEdouard Nice受邀参会演讲_活动家

Edouard Nice,Professor of Monash University, Australia.His scientific research has largely focussed on the development of new techniques (including micropreparative HPLC, biosensor analysis and proteomics) for the micro-isolation, purification, characterisation and analysis of protein and peptide growth factors, their receptors and associated signalling molecules with the aim of understanding the role of these molecules in neoplasia (in particular colorectal cancer (CRC). Many of these studies have been aimed at the discovery and characterisation of potential CRC biomarkers for early the detection and surveillance of the disease. To this end he has pioneered the field of Faecal Proteomics, and the role of quantitative mass spectrometry (using the technique of multiple reaction monitoring (MRM)) for the development and validation of sensitive and specific multiplexed assays for use with panels of CRC biomarkers. This platform technology can be readily translated to other cancers, or other pathologies (e.g. cardiovascular disease, diabetes, neuropathology).He has published more than 200 peer-reviewed manuscripts in highranking International Journals and specialist journals related to his fields of interest. These articles have been cited >8500 times, with an average number of citations per article of 37.85. 16 articles have more > 100 citations. They have an h-index of 50. He has had many successful collaborations with both industry and academia, and holds a number of patents in his field. Ed is on the editorial board of a number of scientific journals including Analytical Biochemistry, Biomedical Chromatography, Expert Review of Proteomics, Current Signal Transduction Therapy and Growth Factors. He was a founding member of the Australian Peptide Association, co-chair and treasurer of the HUPO 2010 meeting in Sydney, is currently one of the leaders of HUPO Chr 7 initiative, is a co-chair of the Cancer HPP initiative and a member of the HUPO antibody and financial committees.